The FDA needs Rybelsus to hold a black box warning—probably the most critical variety of warning—about the risk of thyroid C-mobile tumors. This warning stems from animal experiments demonstrating that semaglutide and related medicines triggered thyroid tumors, which includes cancer, in rodents.